Seeking Alpha

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

BOSTON, April 24, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living ...
Seeking Alpha

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses On Commercial Readiness For Acquired Hypothalamic Obesity Event Call (Transcript)

Good morning, everybody. Thank you for joining us today. I'm Dave Connolly, IR here at Rhythm Pharmaceuticals. Before we begin the speaking program, I'll just remind you that this event may include ...

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of ...